文献速递免疫规划传染病防控与疫情报告

流感与COVID-19疫苗有效性分析中偏倚的评估与缓解——IVY网络,2022年9月1日至2023年3月30日

Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023.
PubMed 文献 · Vaccine · 2024-11-07

美国多中心哨点监测网络前瞻性纳入2022年9月1日至2023年3月31日因急性呼吸道疾病住院的成人,评估检测阴性设计中对照组纳入共循环病原体对疫苗有效性估计的偏倚影响。结果显示,当对照组纳入COVID-19患者时,流感疫苗有效性总体降低6个百分点;当对照组纳入流感患者时,COVID-19疫苗有效性总体降低2个百分点。排除混杂呼吸道病原体可减少向下偏倚。

要点

  • 对照组纳入COVID-19患者使流感疫苗有效性估计降低6个百分点。
  • 对照组纳入流感患者使COVID-19疫苗有效性估计降低2个百分点。
  • 排除混杂呼吸道病原体是减少向下偏倚的有用策略。

核心结论

  • 在疫苗有效性分析中,从对照组排除混杂呼吸道病原体病例可减少向下偏倚,尤其对流感疫苗有效性测量有帮助。

研究设计与样本

  • 美国多中心哨点监测网络前瞻性纳入2022年9月1日至2023年3月31日因急性呼吸道疾病住院的成人。

主要发现

  • 当对照组纳入COVID-19患者时,流感相关住院的总体疫苗有效性降低6个百分点。
  • 当对照组纳入流感患者时,COVID-19相关住院的总体疫苗有效性降低2个百分点。
  • 对共循环病毒和RSV假结局的疫苗有效性分析显示,向下偏倚主要归因于疫苗接种状态跨病原体的相关性,也可能归因于疫苗有效性模型中的其他残余混杂来源。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In test-negative studies of vaccine effectiveness (VE), including patients with co-circulating, vaccine-preventable, respiratory pathogens in the control group for the pathogen of interest can introduce a downward bias on VE estimates. METHODS: A multicenter sentinel surveillance network in the US prospectively enrolled adults hospitalized with acute respiratory illness from September 1, 2022-March 31, 2023. We evaluated bias in estimates of VE against influenza-associated and COVID-19-associated hospitalization based on: inclusion vs exclusion of patients with a co-circulating virus among VE controls; observance of VE against the co-circulating virus (rather than the virus of interest), unadjusted and adjusted for vaccination against the virus of interest; and observance of influenza or COVID-19 against a sham outcome of respiratory syncytial virus (RSV). RESULTS: Overall VE against influenza-associated hospitalizations was 6 percentage points lower when patients with COVID-19 were included in the control group, and overall VE against COVID-19-associated hospitalizations was 2 percentage points lower when patients with influenza were included in the control group. Analyses of VE against the co-circulating virus and against the sham outcome of RSV showed that downward bias was largely attributable the correlation of vaccination status across pathogens, but also potentially attributable to other sources of residual confounding in VE models. CONCLUSION: Excluding cases of confounding respiratory pathogens from the control group in VE analysis for a pathogen of interest can reduce downward bias. This real-world analysis demonstrates that such exclusion is a helpful bias mitigation strategy, especially for measuring influenza VE, which included a high proportion of COVID-19 cases among controls.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lewis NM, Harker EJ, Leis A, et al. Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023. Vaccine. 2024. PMID: 39515195. doi:10.1016/j.vaccine.2024.126492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。